Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.

By E. Schiffrin, J. Park, H. Intengan, Rhian M. Touyz. Circulation, 2000

638 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Endothelial dysfunction. (2004, background): “Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors have been shown to be especially beneficial (6,69,70) (Figure 1).”
Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. (2000, positive): “…or AT 1 receptor antagonist treatment of essential hypertensive patients regresses structural and functional abnormalities of the vascular wall (Schiffrin, 1996, 1998; Schiffrin et al., 2000) suggest that Ang II plays a critical role in abnormal behavior of vascular cells in hypertension.”
The Vascular Endothelium and Human Diseases (2013, background): “Endothelial cell damage occurs in many vascular beds during hypertension (52,53).”
Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study (2006, neutral): “Glucose, mg/dL 110 (38) 110 (38) 112 (38) 112 (38)”
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. (2007, background): “Studying the varied roles of Ang II is also of tremendous importance given the beneficial effects of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) in reducing morbidity and mortality in diabetes, hypertension, atherosclerosis, heart failure, and stroke (69”